E-Z-EM PREP LYTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for E-Z-EM PREP LYTE (E-Z-EM PREP LYTE).
Polyethylene glycol (PEG) 3350 is an osmotic laxative that induces diarrhea by retaining water in the bowel, thereby cleansing the colon. Electrolytes (sodium sulfate, sodium chloride, potassium chloride) are added to prevent electrolyte imbalance.
| Metabolism | PEG 3350 is not significantly metabolized; it is excreted unchanged in feces. Electrolytes are absorbed or excreted via renal and gastrointestinal pathways. |
| Excretion | Renal elimination of absorbed polyethylene glycol (PEG) is approximately 50-70% unchanged; the remainder is excreted in feces. Electrolytes are absorbed and renally excreted. |
| Half-life | The terminal elimination half-life of PEG 3350 is approximately 4-6 hours; clinical effects are largely non-systemic due to minimal absorption. |
| Protein binding | PEG 3350: negligible protein binding (<1%); no specific binding proteins identified. |
| Volume of Distribution | Vd for PEG 3350 is approximately 0.2-0.3 L/kg; reflects distribution primarily in extracellular fluid with minimal tissue penetration. |
| Bioavailability | Oral bioavailability of PEG 3350 is approximately 10-20% due to minimal gastrointestinal absorption; electrolytes are absorbed systemically. |
| Onset of Action | Oral: onset of bowel evacuation typically occurs within 0.5-1 hour after ingestion; full effect within 2-4 hours. |
| Duration of Action | Duration of laxative effect is approximately 1-3 hours after onset; complete bowel evacuation occurs within 4-6 hours. |
Oral: 4 liters as a single dose for colonoscopy preparation.
| Dosage form | FOR SUSPENSION |
| Renal impairment | Contraindicated in patients with GFR < 30 mL/min; for GFR 30-60 mL/min, use with caution and ensure adequate hydration. |
| Liver impairment | No specific adjustment for Child-Pugh class A or B; for class C, use only if benefits outweigh risks due to potential for fluid overload. |
| Pediatric use | Not indicated for patients under 18 years of age. |
| Geriatric use | Use with caution due to increased risk of aspiration and electrolyte imbalance; consider split-dose regimen. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for E-Z-EM PREP LYTE (E-Z-EM PREP LYTE).
| Breastfeeding | No human data on excretion in breast milk. Electrolytes (sodium, potassium, magnesium) are normal milk constituents. M/P ratio unknown. While systemic absorption is minimal, consider risks of maternal dehydration or electrolyte imbalance. Use with caution in nursing mothers. |
| Teratogenic Risk | E-Z-EM PREP LYTE is a balanced electrolyte solution (sodium sulfate, magnesium sulfate, potassium chloride) for colonoscopy preparation. There are no adequate and well-controlled studies in pregnant women. Animal studies are not available. The risk of electrolyte imbalance and dehydration may increase fetal risk if used improperly. In the first trimester, theoretical risks from electrolyte shifts; second and third trimesters, risk of maternal dehydration leading to reduced placental perfusion. Use only if clearly needed. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Gastrointestinal obstruction or perforation","Ileus or toxic megacolon","Severe renal impairment (e.g., creatinine clearance <30 mL/min)","Known hypersensitivity to any component","Active severe colitis"]
| Precautions | ["Risk of electrolyte abnormalities (e.g., hypernatremia, hypokalemia) in patients with renal impairment or those taking diuretics","Aspiration risk, especially in patients with impaired gag reflex or swallowing disorders","Use caution in patients with colitis, toxic megacolon, or gastrointestinal obstruction","Potential for cardiac arrhythmias due to electrolyte shifts","Dehydration and fluid overload risk in elderly or debilitated patients"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal electrolytes (sodium, potassium, magnesium, calcium) before and during administration. Assess fluid balance, renal function, and signs of dehydration. Fetal monitoring may be indicated if maternal fluid or electrolyte disturbances occur. |
| Fertility Effects | No human data on fertility effects. Animal reproduction studies have not been conducted. Imbalances in electrolytes could theoretically affect reproductive function. No known direct effect on fertility. |